Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Artemisia study
2023-510291-32-00Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial in asthma comparing AZD4604 with Placebo (2 arms). Primary endpoint: Change from baseline to end of IMP administration in expression of T2, non-T2, and JAK1-related genes and gene signatures in bronchial brushings. Started Sep 2024; status: completed.
02
Drugs
londamocitinib
03
Conditions
asthma
Beyond the preview
Go deeper on 2023-510291-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510291-32-00.